Alkermes plc (ALKS)

Market Cap	4.81B
Revenue (ttm)	1.51B
Net Income (ttm)	333.35M
Shares Out	161.80M
EPS (ttm)	1.97
PE Ratio	13.00
Forward PE	14.02
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,063,346
Open	29.76
Previous Close	29.97
Day's Range	29.53 - 30.37
52-Week Range	22.90 - 32.88
Beta	0.46
Analysts	Buy
Price Target	35.42 (+19.22%)
Earnings Date	Feb 13, 2025

About ALKS

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable su...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jul 16, 1991
• Employees: 2,100
• Stock Exchange: NASDAQ
• Ticker Symbol: ALKS
• Website: https://www.alkermes.com

Analyst Forecast

According to 12 analysts, the average rating for ALKS stock is "Buy." The 12-month stock price forecast is $35.42, which is an increase of 19.22% from the latest price.

Price Target

$35.42

(19.22% upside)

Analyst Consensus: Buy